Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 4, 2024Hematology Transfusion and Cell TherapyOpen Access

Outcomes of upfront plerixafor use for mobilization in germ cell tumor patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJaimie CohenUniversity of Miami Health SystemSSSulsha ShahGujarat UniversityKPKatrina M PiedraUniversity of Miami Health System

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cohen et al. (2024) studied this question.

synapsesocial.com/papers/68e75dd0b6db6435876d4c8fhttps://doi.org/10.1016/j.htct.2023.12.008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma2009 · 687 citations
  2. 2Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy2010 · 324 citations